Adjunctive rifampicin for Staphylococcus aureus bacteraemia (ARREST): a multicentre, randomised, double-blind, placebo-controlled trialGuy Thwaites, Elian Liu, Matthew Scarborough et al.|The Lancet|2017Cited by 186
World Sepsis Day: a global agenda to target a leading cause of morbidity and mortalityLuregn J. Schlapbach, Konrad Reinhart, Niranjan Kissoon et al.|American Journal of Physiology-Lung Cellular and Molecular Physiology|2020Cited by 70
Adjunctive rifampicin to reduce early mortality from Staphylococcus aureus bacteraemia (ARREST): study protocol for a randomised controlled trialGuy Thwaites, A. Sarah Walker, Cressida Auckland et al.|Trials|2012Cited by 27
Reducing the global burden of sepsis: a positive legacy for the COVID-19 pandemic?Luregn J. Schlapbach, Konrad Reinhart, Simon Finfer et al.|Intensive Care Medicine|2021Cited by 27
Procalcitonin testing combined with NEWS2 evaluation compared with usual care based on NEWS2 for identification of sepsis and antibiotic initiation in the emergency department in England and Wales (PRONTO): a multicentre, randomised, controlled, open-label, phase 3 trialStacy Todd, Stephanie Gilbert, Philip Howard et al.|The Lancet Respiratory Medicine|2026Cited by 1